Virtual Service Boosts Glycemic Control in Hospitalized Adults

Share this content:
Virtual Service Boosts Glycemic Control in Hospitalized Adults
Virtual Service Boosts Glycemic Control in Hospitalized Adults

TUESDAY, March 28, 2017 (HealthDay News) -- Implementation of a virtual glucose management service (vGMS) is associated with improved inpatient glycemic control, with decreases in hypoglycemia and hyperglycemia, according to a study published online March 28 in the Annals of Internal Medicine.

Robert J. Rushakoff, M.D., from the University of California in San Francisco, and colleagues conducted cross-sectional analyses of three 12-month periods (pre-vGMS, transition, and vGMS) to determine the correlation with glycemic control at three hospitals. Data were included for hospitalized adults with two or more glucose values of 12.5 mmol/L or greater (hyperglycemic) and/or a glucose level below 3.9 mmol/L (hypoglycemic) in the previous 24 hours.

The researchers observed a 39 percent decrease in the proportion of hyperglycemic patients, from 6.6 to 4.0 per 100 patient-days in the pre-vGMS to the vGMS period (difference, −2.5). The hypoglycemic proportion was 36 percent lower in the vGMS period versus the pre-vGMS period (difference, −0.28). In the pre-vGMS and vGMS periods there were 40 and 15 severe hypoglycemic events, respectively.

"Implementation of the vGMS was associated with decreases in hyperglycemia and hypoglycemia," the authors write.

One author disclosed financial ties to Google.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »